BioSpace News Archive

Origin Therapeutics Holdings Inc.(CSE: ORIG) (the “Company”, “Origin Therapeutics” or “Origin”) today announced that one of its portfolio companies, Clairvoyant Therapeutics (“Clairvoyant”), has received regulatory approval from the Finnish Medicines Agency (FIMEA) to proceed with the company’s Phase 2 clinical trial investigating psilocybin for the treatment of alcohol use disorder (AUD) in Finland.

Thought leaders from McKesson will play a major role in the upcoming 2022 Association for Value-Based Cancer Care (AVBCC) Summit, speaking on a wide range of topics that showcase their extensive knowledge of the changing healthcare landscape and oncology’s transformation to value-based care.

AcuraBio (formerly Luina Bio), a leading Australian biopharmaceutical CDMO, recently acquired by biotech investor Dr. Glenn Haifer and Ampersand Capital Partners, announced today new senior executive hires to support global growth plans.

China’s research and development industry has recently been flourishing with support from the government’s newer policies and increasing investment

Evozyne named Zach Serber as its chief operating officer, a newly created position charged with directing scientific operations for the fast-growing biology engineering company.

Calgary-based genomics and precision health company, BioAro, is launching its comprehensive genetic and microbiome testing services.

Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today, the presentation of nine scientific presentations with data from its current antibiotic portfolio at Infectious Disease Week (IDWeek) 2022, taking place October 19– 22, 2022, in Washington, D.C.

Pfizer Inc. (NYSE: PFE) will share data across its expansive infectious disease portfolio, including company-sponsored and collaborative research studies, spanning both licensed and investigational vaccines, and antibiotic and antiviral therapies at IDWeek 2022 held in Washington, D.C. October 19-23, 2022.

The global In Vitro Diagnostics (IVD) Quality Control market gathered revenue around USD 1.0 Billion in 2020 and market is set to grow USD 2.9 Billion by the end of 2027 and is estimated to expand at a modest CAGR of 6.2% during the prediction period 2021 to 2027.

Berkeley Lights, Inc., a leader in digital cell biology, announced that the Company will be reporting financial results for the third quarter 2022 after market on Tuesday, November 8, 2022.